Pentostatin

Nucleoside Metabolic Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Pentostatin is an ofp drug in the Nucleoside Metabolic Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1991. Its mechanism of action is classified as Nucleic Acid Synthesis Inhibitors. DrugCentral lists 3 molecular targets, including ADA, ADA and Adenosine deaminase. Recorded indications include Hairy cell leukemia.

• Approval status: ofp (first approved 1991 by the FDA).
• Drug class: Nucleoside Metabolic Inhibitor.
• Mechanism of action: Nucleic Acid Synthesis Inhibitors.
• Molecular targets: ADA, ADA and Adenosine deaminase (3 listed in DrugCentral).
• Indications: Hairy cell leukemia.
• ATC code: L01XX08 (Other antineoplastic agents).
• Molecular formula: C11H16N4O4; molecular weight 268.27 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Hairy cell leukemia

Off-label uses (1)

• Chronic lymphoid leukemia, disease

Contraindications (14)

• Anemia
• Bone marrow depression
• Breastfeeding (mother)
• CNS Toxicity
• Disease of liver
• Infectious disease
• Kidney disease
• Leukopenia
• Liver function tests abnormal
• Low blood pressure
• Neutropenic disorder
• Pregnancy, function
• Pulmonary edema
• Thrombocytopenic disorder

Mechanism & targets

• Mechanism of action (MoA): Nucleic Acid Synthesis Inhibitors
• Established pharmacologic class: Nucleoside Metabolic Inhibitor

Molecular targets (3)

Target	Gene	Action	Activity
Adenosine deaminase	ADA	unknown	Ki 11.00
Adenosine deaminase	ADA	inhibitor	IC50 10.80
Adenosine deaminase	—	unknown	Ki 10.42

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1991-10-11	FDA	—	HOSPIRA INC	Yes

ATC classification

ATC code	Therapeutic hierarchy
L01XX08	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Other antineoplastic agents

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
BK virus infection	120.7
Cystitis haemorrhagic	83.5
Renal tubular injury	73.3
Thrombotic microangiopathy	69.3
Neutropenia	58.7
Hairy cell leukaemia recurrent	46.0
Tumour lysis syndrome	45.4
Autoimmune haemolytic anaemia	43.5
Acute graft versus host disease	42.8
Sepsis	41.3
Thrombocytopenia	39.6
Bronchopulmonary aspergillosis	39.4

Chemical structure

• Molecular formula: C₁₁H₁₆N₄O₄
• Molecular weight: 268.27 g/mol
• CAS number: —
• InChIKey: FPVKHBSQESCIEP-JQCXWYLXSA-N
• PubChem CID: 439693

OC[C@H]1O[C@H](C[C@@H]1O)N1C=NC2=C1NC=NC[C@H]2O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Pentostatin used for?

DrugCentral lists the following indications for Pentostatin: Hairy cell leukemia.

How does Pentostatin work?

Pentostatin is classified as Nucleic Acid Synthesis Inhibitors; its molecular targets in DrugCentral include ADA, ADA (inhibitor) and Adenosine deaminase.

When was Pentostatin first approved?

Pentostatin was first approved by the FDA in 1991.

What drug class does Pentostatin belong to?

Pentostatin is in the Nucleoside Metabolic Inhibitor class.

What is the chemical formula of Pentostatin?

Pentostatin has the molecular formula C11H16N4O4 and a molecular weight of 268.27 g/mol.

Sources

• DrugCentral drug card 2098 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1580 — compound record and bioactivity
• PubChem CID 439693 — chemical identifiers
• DrugBank DB00552 — drug record
• FDA UNII 395575MZO7 — substance identity
• DailyMed: FDA labels for Pentostatin — current prescribing information (label search)
• UniProt P00813 (ADA) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.